Share
The pharma industry briefing
The latest news, approvals and clinical trials you need to know about this month
Data:
News
in Numbers
10-15
The average number of years it takes to get a new drug to market
$121m
The amount Recursion Pharmaceuticals has raised to map how disease affects cells
10,574
Type II spinal muscular atrophy totalled 10,574 cases in 2018, the highest among all the subtypes
7%
Statistics on the number of animals used in research in the UK last year show a decrease of 7% on the 2017 numbers
$390m
Novartis has offloaded lagging endocrine drugs to Recordati for $390m
Data:
News
in Numbers
10-15
The average number of years it takes to get a new drug to market
$121m
The amount Recursion Pharmaceuticals has raised to map how disease affects cells
10,574
Type II spinal muscular atrophy totalled 10,574 cases in 2018, the highest among all the subtypes
7%
Statistics on the number of animals used in research in the UK last year show a decrease of 7% on the 2017 numbers
$390m
Novartis has offloaded lagging endocrine drugs to Recordati for $390m
How do you test a new seasickness drug? Take pill, set sail
Vanda, a small biopharmaceutical company based in Washington, has completed the second phase of clinical trials of a motion-sickness drug it hopes will compete with industry leader Dramamine
Source: Bloomberg
Takeda looking to divest portfolio of older drugs in Europe
Takeda is trying to sell a portfolio of older drugs in western Europe as it seeks to cut its debts following the $59bn purchase of Shire.
Source: Pharmaphorum
Patent panic gives green light to mega pharma deals
Pressure drugmakers face over expiries means big takeovers can lack scrutiny.
Source: The Financial Times
Top Indian drugmakers expand in China
Cipla has announced that it is forming a Chinese joint venture with local firm Jiangsu Acebright Pharmaceutical. The new company will set up a manufacturing facility to make respiratory products—a key strength of Cipla's—for the Chinese market.
Source: Fierce Pharma
Celltrion Healthcare joins Australia's pharma industry group
Celltrion Healthcare said that it has joined Australia's Generic and Biosimilar Medicines Association (GBMA), the country's largest biopharmaceutical industrial society.
Source: Korea Biomedical Review
Approvals
Soliris (eculizumab)
The US Food and Drug Administration (FDA) has approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Source: World Pharma News
XPOVIO (selinexor)
The US FDA has approved oral XPOVIOTM, in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma.
Source: Karyopharm Therapeutics
Recarbrio
The FDA has approved a new triple-drug antibiotic, Recarbrio, from Merck & Co, but the company and regulator have cautioned it should only be prescribed for last-ditch use.
Source: Pharmaphorum
Otezla (apremilast)
Otezla (apremilast)—an oral PDE4 inhibitor—has been cleared by the FDA for the treatment of adult patients with mucositis (mouth ulcers) associated with Behçet’s disease.
Source: Celgene
Go to top
Go to top
Share this article
